CRISPR screens identify novel regulators of cFLIP dependency and ligand-independent, TRAIL-R1-mediated cell death

Neil Kuehnle1, Scout Mask Osborne1, Ziyan Liang1

  • 1Department of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Tarry 6-735, Chicago, IL, 60611, USA.

Insights

Cellular FLICE inhibitory protein (cFLIP) is essential for primary effusion lymphoma (PEL) cell survival by inhibiting cell death pathways. KSHV vFLIP cannot fully replace cFLIP, revealing distinct functions and new therapeutic targets.

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • Kaposi's sarcoma-associated herpesvirus (KSHV) drives primary effusion lymphoma (PEL) pathogenesis.
  • PEL cells critically depend on cellular FLICE inhibitory protein (cFLIP) for survival.
  • KSHV encodes a viral FLIP (vFLIP) homolog, raising questions about functional redundancy.

Purpose of the Study:

  • To investigate the essential role of cFLIP in PEL cells.
  • To determine if KSHV vFLIP can functionally substitute for cFLIP.
  • To identify pathways that can compensate for cFLIP loss in PEL cells.

Main Methods:

  • Rescue experiments using different FLIP isoforms and viral homologs.
  • Genome-wide CRISPR/Cas9 synthetic rescue screens.
  • Validation experiments targeting identified pathways and proteins.

Main Results:

  • Human cFLIP isoforms and molluscum contagiosum virus MC159L rescued cFLIP loss, but KSHV vFLIP did not fully rescue.
  • CRISPR screens identified caspase 8 and TRAIL receptor 1 (TRAIL-R1) as key targets.
  • Inactivation of ER/Golgi pathways, UFMylation, Jagunal homolog 1 (JAGN1), or CXCR4 also overcame cFLIP requirement.

Conclusions:

  • KSHV vFLIP is functionally distinct from cFLIP in PEL cells.
  • PEL cell survival relies on cFLIP to suppress ligand-independent TRAIL-R1 cell death signaling.
  • ER/Golgi-associated processes, UFMylation, and JAGN1 are newly implicated in cFLIP and TRAIL-R1 regulation.